Syngene has stepped up its efforts to fight COVID-19
As a predominantly science-based organization (our workforce of 5000 comprises 4200 scientists of which over 450 are PhDs) Syngene was quick to understand the complexity of the problems posed by COVID-19.
At Syngene, we are committed to protecting our workforce, minimizing business disruptions, playing our part in improving human health, and contributing to the government’s initiatives to combat COVID-19. Keeping this in mind, we have adopted a three-pronged strategy to combat COVID-19: protect our employees and contractors, ensure business continuity and leverage our R&D capabilities to combat COVID-19.
Syngene is a voluntary license holder from Gilead for manufacture and sale of Remdesivir for COVID-19 patients. Any queries regarding Remdesivir supply can be directed to our marketing and distribution partners Sun Pharma and Biocon Biologics.
Biocon Biologics helpline (for inquiries within Karnataka) : 1800 425 6286
Sun Pharma helpline (for pan India inquiries other than Karnataka) : 1800 103 1013
*Information supplied in compliance of order dated 02.05.2021 issued by the Bombay High Court (Nagpur Bench) in Suo-Motu P.I.L. No.4 of 2020 (Court on its own motion vs. Union of India and Ors).